Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Stage I/II Nasal NK Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Radiation: Radiation
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2011-03-23

Last Posted Date: 2015-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01321008

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

18-F-Fluoroacetate as PET Imaging Agent

Phase 1

Withdrawn

Conditions: Brain Cancer
Breast Cancer
Prostate Cancer

Interventions: Drug: 18F-fluoroacetate

First Posted Date: 2011-03-22

Last Posted Date: 2014-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01320787

Study of 18F-Fluoro-PEG6-IPQA

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: 18F-PEG6-IPQA
Procedure: Positron emission tomography (PET)

First Posted Date: 2011-03-22

Last Posted Date: 2016-06-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01320059

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Rituximab
Drug: Imatinib
Drug: VSLI
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Solu-Medrol
Drug: Mesna
Drug: Methotrexate
Drug: Ara-C
Drug: G-CSF
Drug: Pegfilgrastim
Drug: Dexamethasone

First Posted Date: 2011-03-22

Last Posted Date: 2022-09-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT01319981

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Diabetic Treatment Adherence

Completed

Conditions: Endocrine System Diseases

Interventions: Drug: Metformin
Behavioral: Questionnaires

First Posted Date: 2011-03-18

Last Posted Date: 2016-09-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT01318564

Locations: 🇺🇸
Kelsey Seybold Clinics, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Other: Placebo
Drug: Armodafinil
Drug: Minocycline
Behavioral: Questionnaires

First Posted Date: 2011-03-17

Last Posted Date: 2020-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT01317550

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

Conditions: Breast Cancer
Prostate Cancer
Colorectal Cancer

Interventions: Behavioral: Standard Arm (mail/telephone)
Behavioral: Internet Arm
Behavioral: Surveys and Questionnaires
Behavioral: Exercise and Diet

First Posted Date: 2011-03-10

Last Posted Date: 2019-05-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT01311856

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Social Determinants and Smoking Cessation

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Questionnaires
Drug: Nicotine Patch Therapy
Behavioral: Counseling Sessions

First Posted Date: 2011-03-09

Last Posted Date: 2016-10-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 329

Registration Number: NCT01310842

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Virtual Reality Intervention in Cancer Genetics

Withdrawn

Conditions: Prevention Harmful Effects
Cancer

Interventions: Behavioral: Questionnaires
Behavioral: Physiological Measurements
Behavioral: Virtual Reality Scene Viewing

First Posted Date: 2011-03-09

Last Posted Date: 2016-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01310829

Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Surgimend
Device: Alloderm

First Posted Date: 2011-03-07

Last Posted Date: 2019-04-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT01310075

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy